trial

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

NCTId NCT01377233
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 46 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2012-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
46 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-07
Primary completion
2012-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Zicronapine open-label lead-in 10 mg dailyZicronapine 10 mg dailyZicronapine 20 mg once weeklyZicronapine 30 mg once weeklyZicronapine 45 mg once weekly

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

4 total
Garden Grove, United StatesNational City, United StatesSan Diego, United StatesRockville, United States

Linked catalysts

1
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapi — primary completion2012-02

Facts & assertions

4 sourced
Enrollment
46
Phase
PHASE2
Primary Completion Date
2012-02
Status
COMPLETED
relationships
The graph out of here
drug
Zicronapine open-label lead-in 10 mg daily
drug
Zicronapine 10 mg daily
drug
Zicronapine 20 mg once weekly
drug
Zicronapine 30 mg once weekly
drug
Zicronapine 45 mg once weekly
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication